Skip to content

Study · Not a test of the peptide alone · 2012

1 result

Endometrial gene expression in the early luteal phase is impacted by mode of triggering final oocyte maturation in recFSH stimulated and GnRH antagonist co-treated IVF cycles.

Humaidan P, Van Vaerenbergh I, Bourgain C, Alsbjerg B, Blockeel C, Schuit F, Van Lommel L, Devroey P, Fatemi H

Human reproduction (Oxford, England)28 Aug 2012Cited by 38 (Europe PMC)

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study1

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone1

In this study, Triptorelin (Trelstar, Decapeptyl) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Triptorelin (Trelstar, Decapeptyl).

  1. 01HumanNot a test of Triptorelin (Trelstar, Decapeptyl) aloneRandomized controlled trialMechanism

    In oocyte donors, triptorelin followed by hCG and standard luteal support produced endometrial expression similar to hCG triggering.

    In plain wordsIn donors, triptorelin followed by hCG and standard luteal support produced gene expression similar to hCG triggering with standard luteal support.

    Outcome
    No significant changeEndometrial gene expression with modified luteal support
    Study

    n = 4

    Comparator
    hCG trigger with standard luteal support
    Outcome group
    Sex hormones and fertility · Reproductive and sexual health

    Source sentences

    Summary
    However, the endometrial gene expression after the GnRH agonist trigger and a modified luteal phase support (B) was similar to the pattern seen after the hCG trigger (A).
    2 context sentences
    Summary · context
    (B) GnRH agonist (triptorelin 0.2 mg), followed by 1500 IU hCG 35 h after triggering final oocyte maturation, and standard luteal phase support
    Summary · context
    A prospective randomized study was performed in four oocyte donors recruited from an oocyte donation program during the period 2010-2011.

    In this study, Triptorelin (Trelstar, Decapeptyl) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Triptorelin (Trelstar, Decapeptyl).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    22 Oct 2026, 02:26 UTC

    Study results updated

  2. Version 1

    21 Oct 2026, 18:59 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.